From a medical standpoint, yes, but not from a commercial standpoint. Many sell-side analysts are still predicting that ABBV/ENTA will garner 15% or less of the GT1 market in the US and EU (compared to my forecast of 38% volume share).
As more analysts raise their market-share forecasts for the 3-DAA regimen, ENTA’s share price will presumably respond accordingly.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.